Cannabinoid Receptor 2 (CNR2) Antibody

Product specifications

Primary Antibodies

Cannabinoid Receptor 2 (CNR2)

Rabbit

Human

ELISA: 1/20000 - 1/80000, WB: 1/500 - 1/2000, IHC: 1/100 - 1/200. Optimal dilutions/concentrations should be determined by the end user.

Polyclonal

Unconjugated

IgG

Purified by Protein A/G column chromatography.

100 µg

1 mg

Lyophilized

ELISA, WB, IHC

Prior to lyophilization: 0.02% NaN3.

Shipped within 7-15 working days.

Store at -20 °C. Avoid repeated freeze/thaw cycles.

No

NM_001841

CNR2,Rcb2,cannabinoid receptor 2,CB2-R,Peripheral cannabinoid receptor, CB-2, CB2, CX5,Cannabinoid Receptor 2 Macrophage

Antibody anti-CNR2

RUO

Concentration: Lyophilized form: Not applicable.  After reconstitution: 1 mg/ml. -

Descripción

Cannabinoid Receptor 2 (CNR2), also known as CB2, is the second major receptor of the endocannabinoid system (ECS) and is predominantly expressed in immune cells, including macrophages, B-cells, T-cells, and microglia. Unlike CB1, CB2 is primarily located in the peripheral nervous system (PNS) and immune system, where it modulates inflammation, immune response, and tissue repair. Activation of CB2 by endocannabinoids like 2-AG or synthetic cannabinoids suppresses pro-inflammatory cytokine release, attenuating inflammatory responses and providing protection against autoimmune diseases and chronic inflammatory conditions such as rheumatoid arthritis and multiple sclerosis. CB2 also plays a critical role in regulating neuroinflammation and protecting neurons in neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and Huntington's disease by reducing oxidative stress and apoptosis. Additionally, CB2 is expressed in tissues like the liver, lungs, and bone, where it regulates processes like fibrosis, wound healing, and bone remodeling, highlighting its importance in diseases like liver fibrosis and osteoporosis. CB2 receptors are not associated with psychoactive effects, making them a promising therapeutic target for chronic pain, neuropathic pain, and cancer. CB2 agonists are actively being developed for clinical applications, particularly in inflammation, immune modulation, and cancer therapy, where CB2 activation can suppress tumor growth and metastasis. Ongoing research into CB2 biology underscores its potential as a non-psychoactive therapeutic target for a wide range of inflammatory, neurodegenerative, and immune-related disorders.

Related Products

Mouse CNR2 (Cannabinoid Receptor 2) ELISA Kit

Ver Producto

Cannabinoid Receptor 2 (CB2) Antibody

The cannabinoid delta-9-tetrahydrocannabinol is the principal psychoactive ingredient of marijuana. The proteins encoded by this gene and the cannabinoid receptor 1 (brain) (CNR1) gene have the characteristics of a guanine nucleotide-binding protein (G-protein) coupled receptor for cannabinoids. They inhibit adenylate cyclase activity in a dose-dependent, stereoselective, and pertussis toxin-sensitive manner. These proteins have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. The cannabinoid receptors are members of family 1 of the G-protein-coupled receptors.

Ver Producto

Cannabinoid Receptor 2 (CNR2) Antibody

Rabbit Polyclonal against the Cannabinoid receptor 2 protein.

Ver Producto